Kenneth Pickle

IMG_8933Kenneth joined the Radice Law Firm as an associate in 2013.

Prior to law school, he was an analytical chemist for a large pharmaceutical company. His litigation experience includes representing plaintiffs in all phases of litigation, including case evaluation and assessment, development of case strategy, all phases of discovery, trial strategy development, and trial. He has been part of the litigation or trial teams in numerous class actions against pharmaceutical companies alleging anticompetitive delayed-generic entry business practices, including:

  • In re Celebrex Antitrust Litigation, 14-cv-361 (E.D. Va.) ($94 million settlement in case alleging that Pfizer engaged in fraud before the Patent Office in securing patent protection for its blockbuster pain drug)
  • In re Skelaxin (metaxalone) Direct Purchaser Antitrust Litigation, 12-md-2343 (E.D. Tenn.) ($73 million settlement in case alleging delayed generic entry)
  • In re Nexium (Esomeprazole) Antitrust Litigation, 12-md-2409 (D. Mass.) ($24 million partial mid-trial settlement in “pay-for-delay” case challenging agreements between AstraZeneca and generic competitors to delay generic entry)
  • In re Intuniv Antitrust Litigation, 16-cv-12653 (D. Mass.) ($78 million in settlements on behalf of direct purchasers alleging that Shire and Actavis anticompetitively delayed entry of a generic version of Shire’s ADHD drug)
  • In re Xyrem (sodium oxybate) Antitrust Litigation, 20-md-2966 (N.D. Cal.) ($198.4 million in settlements on behalf of end payors alleging anticompetitive reverse payment)

Mr. Pickle graduated from Cardozo Law School in 2011, where he served as associate editor for the Cardozo Journal of International and Comparative Law. He is admitted to the bar of the State of New York, as well as the U.S. District Courts for the Southern District of New York and Eastern District of New York. He is also a registered patent attorney with the U.S. Patent and Trademark Office.